0 results for 'Marshall Gerstein & Borun LLP'
IP: Third party pre-issuance submissions
A third party trying to reduce the claim breadth in a competitors pending patent application may wind up doing more harm than goodIP: The late claimed invention and the written description defense
An early determination that a patent claim is likely unsupported can be important in setting negotiation and litigation strategy for both the patent owner and the potential purchaser or accused infringer.IP: How reissue patents may help you sleep at night
Reissue patents should be considered at the outset by applicants looking to save costs and by applicants who are filing very early in the development of a potential commercial product.IP: Patent exhaustion clarification from the Federal Circuit
The Federal Circuit answered whether, if a product is given away and the patent owner did not receive any compensation, the distribution of that product exhausted the patent claim.IP: Mr. (Patent Attorney) Smith Goes to Washington - Successful patent examiner interviews
Some inside practice tips for the time spent leading to, during, and immediately following an in-person interview at the USPTO.IP: Unintended consequences when licensing patented technology
When licensing or purchasing technology that may include patented inventions, the negotiating parties will have many legal and business priorities to consider.Skadden, Manatt Snag Roles on Major NYC Hospital Merger
The Mount Sinai Medical Center has turned to Skadden, Arps, Slate, Meagher & Flom for counsel on its proposed merger with Continuum Health Partners, which is being advised by Manatt, Phelps & Phillips. The deal would create one of the nation's largest nonprofit hospital chains. Tax filings by Mount Sinai and Continuum reveal how much Skadden and other Am Law 100 firms have been paid over the past few years.15 noteworthy in-house career moves
Charting some of the most recent GC and in-house appointmentsIP: Are “pay for delay” payments anti-competitive or just another settlement agreement?
In a 5-3 decision in FTC v. Actavis, the Supreme Court addressed the question of whether reverse settlement, or pay for delay, payments from an innovator drug company to a generic drugmaker to delay entry into the market constitute an antitrust violation.Trending Stories
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
State Lawmakers Targeting Plastic Pollution in 2024
Brought to you by LexisNexis®
Download Now
Leveraging Technology to Increase Law Firm Profitability
Brought to you by Tranch
Download Now
2024 Report: State of AI in Legal
Brought to you by Ironclad
Download Now
Blueprint for Successful Second Request Document Review
Brought to you by Integreon
Download Now